Skip to main content Back to Top
Advertisement

Current State of Asks to Congress

Broadcast Date: October 26, 2022

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Tom Kraus and Nick Gentile will be discussing the current state of ASHP’s advocacy priorities since our members went to Capitol Hill in mid-September. They will be discussing federal provider status, protecting the 340B program, the elimination of the X waiver, and residency funding audits.

SPEAKERS

Tom KrausTom Kraus is Vice President for Government Relations at ASHP. He is a graduate of University of Michigan (BS Biology), Georgetown University Law Center (Doctor Of Law), and The Johns Hopkins University (MHS, Health Policy).

Tom previously served as the Chief of Staff and Associate Commissioner for Legislation at the U.S. Food and Drug Administration. He was also a senior policy advisor to Sen. Ted Kennedy and Sen. Tom Harkin on the Senate Health, Education, Labor and Pensions Committee, where he served as Deputy Staff Director for Health.

Nick GentileNick Gentile is the Director of Political Action Committee and Grassroots Engagement for the American Society of Health-System Pharmacists. In this position, he promotes ASHP’s grassroots mobilization efforts and its political action committee, ASHP-PAC. He received his bachelor’s degree from The American University, where he majored in political science and law in society. Prior to ASHP, Nick spent ten years at the National Association of Home Builders (NAHB) working in various positions within the government affairs department. He worked with state and local government affairs issues, federal relations, grassroots mobilization and BUILD-PAC (NAHB’s political action committee).

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.